Dilated Cardiomyopathy

Meet the patient

A 29-year-old man walks into clinic with three months of breathlessness on the stairs, two pillows at night, and a 5 kg weight loss. His father died suddenly at 44 — "a heart attack, they said". The echo shows a globally dilated, thin-walled left ventricle with an ejection fraction of 30 percent and functional mitral regurgitation. The coronary angiogram is clean.^[1][2]

Two exam questions are now live and you must answer both at consultant depth: why is this ventricle failing? (the aetiology hunt decides whether the disease is reversible) and what will keep him alive? (the four pillars, the ICD conversation, and the family he has not yet screened). Hold those two questions and the rest of the page slots into place.^[1][3]

The 117-45 rule — the named number that makes the diagnosis

Dilated cardiomyopathy is defined by two numbers and one exclusion. The 2016 ESC revised definition (Pinto) made the diagnosis objective so that "it looks dilated to me" would no longer pass: the LV must be dilated AND systolic, AND the picture must not be explained by loading or by coronary disease.^[2]

The two numbers every candidate must reproduce verbatim:^[2]

• LV end-diastolic dimension (LVEDD), corrected for age and body surface area by the Henry formula, greater than 117 percent of the predicted value. The 2-SD cut-off is 112 percent; the 117 percent figure is 2 SD plus 5 percent, and is used because it adds specificity.
• LV ejection fraction under 45 percent (or fractional shortening under 25 percent).^[1][2]

The one exclusion that does the heavy lifting: the systolic dysfunction must be unexplained by abnormal loading conditions (hypertension, valve disease, congenital heart disease) or by coronary artery disease sufficient to cause global systolic impairment. A dilated, failing ventricle with two-vessel CAD and a prior anterior Q-wave MI is ischaemic cardiomyopathy, not DCM — and the management fork is different.^[1][2]

The number rule — call it 117-45. Say it as one breath in the viva: one-seventeen, forty-five, not loading, not ischaemic. That is the definition, and the rest of the page exists to defend those four words.^[2]

Etymology for viva gold: cardiomyopathy, Greek kardia (heart) plus mys (muscle) plus pathos (suffering) — literally "disease of the heart muscle". The name survived because it excludes the three things the failing heart is NOT failing from: blocked arteries, leaking valves, or high pressure. Once those are gone, what remains is the muscle itself.^[1]

Read the scar like the consultant does — the CMR LGE face-off

Cardiac MRI is the single highest-yield test in dilated cardiomyopathy, and the late-gadolinium-enhancement pattern is the discriminator examiners probe. Echo confirms the dilatation and the EF; CMR tells you why and who will die suddenly.^[5]

The LGE pattern localises the disease in one image:^[5]

^[5]

The discriminator line: mid-wall = DCM; subepicardial inferolateral = myocarditis or sarcoid; subendocardial coronary = ischaemia (leave the DCM pathway); no scar = best prognosis. One sentence, and you have the highest-yield marks on the page.^[5]

Why the ventricle dilates — five mechanisms, one final common pathway

DCM is not one disease — it is a final common pathway that many insults converge on. Genetic mutations, toxins, inflammation, tachycardia and metabolic derangement all end at the same five cellular events.^[1][3]

Enlarge

1. Cardiomyocyte loss and impaired contractility. In genetic DCM, mutations in sarcomeric (TTN, MYH7, TPM1, TNNT2), Z-disc and cytoskeletal (DES, BAG3), nuclear-envelope (LMNA, EMD) and ion-channel or desmosomal (FLNC, PLN, SCN5A) proteins build a contractile apparatus that cannot withstand the cyclical load. Titin-truncating variants are the single commonest — the giant titin filament spans the sarcomere, and a truncation disrupts passive-tension sensing until the myocyte dies and is replaced by scar. In anthracycline injury, free-radical and topoisomerase damage does the same killing.^[1]

2. Adverse remodelling. Loss of myocardium raises wall stress — Laplace: stress is proportional to (pressure times radius) divided by (twice wall thickness). Surviving myocytes slip past one another, the ventricle thins and dilates, and the mitral and tricuspid annuli stretch open into functional regurgitation. More volume returns, the chamber dilates further — a vicious cycle.^[1]

3. Neurohormonal activation. The falling cardiac output is read as underperfusion: the sympathetic system fires catecholamines (chronically cardiotoxic — apoptosis, arrhythmia, hypokalaemia), the RAAS activates (angiotensin II vasoconstricts and drives fibrosis; aldosterone retains sodium and fibroses), and vasopressin rises (dilutional hyponatraemia). Each is initially compensatory, each is chronically toxic — and each is the target of one pillar of therapy.^[3]

4. Fibrosis and arrhythmogenesis. Replacement fibrosis — visible as late gadolinium enhancement — replaces lost myocytes with non-conducting scar. Conduction slows, re-entry circuits form, and the substrate for ventricular arrhythmia and sudden death is born. Mid-wall septal LGE is the strongest CMR predictor of SCD in DCM (Gulati, JAMA 2013).^[5]

5. Stasis and thromboembolism. The dilated, poorly contracting apex becomes a low-flow chamber. Combine that with atrial fibrillation from atrial stretch and endothelial dysfunction, and the patient generates apical mural thrombus and systemic emboli — the rationale for anticoagulation when EF is low, AF is present, or a thrombus is seen.^[1]

Always find the treatable cause before you say idiopathic

The most useful sentence in DCM is "the cause is treatable". Alcohol, tachycardia, thyroid disease, iron deficiency, sarcoidosis, the peripartum state and anthracycline exposure are all reversible or arrestable — and "idiopathic DCM" is usually a diagnosis you made before you finished the work-up.^[1]

Enlarge

Aetiology is the clinically useful axis because it decides reversibility. The familial proportion is 30 to 50 percent (inheritance is usually autosomal-dominant), and titin is the single largest gene — truncating TTN variants were found in roughly 25 percent of familial and 18 percent of sporadic idiopathic DCM in the sequencing study that established this.^[26] A three-generation pedigree — capturing every sudden death under 50, every pacemaker or ICD, every transplant, every unexplained heart failure — is the cheapest, highest-yield piece of the work-up.^[1][27]

^{[1] [1] [6] [8] [26] [32] [33] [34]}

The DILATED mnemonic — carry it onto the ward round and you will not miss a reversible cause:^[1]

^{[1] [1]}

The classic trap — the dilated LV that is actually ischaemic

Before you write DCM, you must exclude the mimics — and ischaemic cardiomyopathy is the one that matters most. Invasive coronary angiography or CTCA to rule out significant coronary disease is part of the initial assessment of every patient with unexplained cardiac dysfunction, because the management fork (revascularisation versus genetic testing and family screening) hangs on getting this right.^[2][27]

^{[1] [5]}

The discriminator line: subendocardial LGE in a coronary territory is ischaemia — leave the DCM pathway and go to the cath lab. Everything else is a clinical-plus-imaging judgement, but that one is categorical.^[1]

The classic trap: a young person with a dilated LV and normal coronaries is not necessarily "idiopathic" — the commonest missed causes are a silent recent viral myocarditis (CMR shows subepicardial inferolateral LGE and T2 oedema), an unrecognised tachycardiomyopathy (quantify the PVC burden on Holter — a burden above 24 percent is the best discriminator, and burdens as low as 10 percent have caused reversible dysfunction), and a family history nobody took. Idiopathic is a label of exclusion, never a working diagnosis.^[1][6][34]

The four pillars together, then the device — the management spine

Enlarge

^[4]

DCM management has four layers: treat the cause, the four pillars of HFrEF, device therapy, and advanced therapies — in that order. The cause work-up runs in parallel with the first prescription; the device decision waits at least three months for the GDMT to work.^[3][4]

Layer 1 — Treat the cause

Name the intervention alongside the cause, because that is how it is examined:

• Alcohol abstinence — in a long-term cohort, continued drinking was a strong predictor of cardiac death in alcoholic DCM;^[24] in a 4-year prospective cohort, abstainers and those who cut down to no more than 60 g of ethanol per day gained about 13 and 12.5 LVEF points respectively at one year, while those who kept drinking over 80 g per day deteriorated.^[32] Refer to alcohol-liaison services.
• Tachycardia-induced — rate or rhythm control (beta-blocker, ablation for a focal atrial tachycardia or high-burden PVCs); the ventricle often recovers once the rhythm is controlled.
• Thyroid disease — levothyroxine for hypothyroidism; carbimazole for thyrotoxicosis.
• Iron deficiency — IV ferric carboxymaltose improves symptoms, functional capacity, and quality of life in HFrEF irrespective of anaemia (FAIR-HF).^[14]
• Haemochromatosis — therapeutic phlebotomy or iron chelation; halts progression if caught early.
• Sarcoidosis — corticosteroids (tapered course) for biopsy-proven or FDG-PET-positive cardiac sarcoid.
• Autoimmune myocarditis (virus-negative, biopsy-proven) — immunosuppression; giant-cell myocarditis demands urgent combination immunosuppression and transplant evaluation.
• Peripartum cardiomyopathy — pregnancy-compatible GDMT plus bromocriptine (see the named subtypes below).^[15][16][30]

Layer 2 — The four pillars of HFrEF, started together

Each pillar carries an independent mortality benefit. Start all four together at low dose and titrate to target — do not sequence them, and do not wait for "the patient to settle" first.^[3][4]

^{[1] [3] [4] [10] [25] [27]}

Named evidence for the consultant viva — carvedilol. In the US Carvedilol Heart Failure Program (Packer, NEJM 1996), 1094 patients with LVEF 35 percent or less were randomised on top of digoxin, diuretic and an ACE-inhibitor: mortality was 7.8 percent on placebo versus 3.2 percent on carvedilol, a 65 percent risk reduction, and the trial was stopped early.^[25] The companion mild-symptoms trial (Packer, Circulation 1996) cut clinical progression of heart failure by 48 percent.^[10] Guidelines treat bisoprolol, carvedilol and metoprolol succinate as interchangeable evidence-based choices — no beta-blocker has been shown superior specifically in non-ischaemic DCM.^[27]

Adjuncts beyond the four pillars:^[21]

• Loop diuretic — the goal in congestion is relief of congestion to euvolaemia, mainly with diuretic therapy; diuretic resistance and electrolyte disturbance are the practical limits.^[21]
• Ivabradine — sinus rhythm with heart rate 70 or more despite maximally tolerated beta-blocker in symptomatic HFrEF; heart-rate reduction with ivabradine cut the composite of cardiovascular death or hospital admission for worsening heart failure (SHIFT).^[19]
• Hydralazine-nitrate — Black patients with symptomatic HFrEF despite standard therapy, or ACEi/ARNI intolerance; the fixed-dose hydralazine-isosorbide dinitrate combination reduced mortality on top of standard therapy in A-HeFT.^[18]
• Digoxin — did not reduce overall mortality but cut hospitalisations overall and for worsening heart failure (DIG); still used for symptom control and rate control in AF; avoid in renal failure and conduction disease.^[20]

Layer 3 — Device therapy, and the DANISH trap

The device decision waits at least three months for the GDMT to do its work — because EF recovers, especially in non-ischaemic DCM, and a device you implanted in month one may be unnecessary by month four.^[3][4]

ICD for primary prevention of sudden cardiac death is offered at EF 35 percent or less, NYHA II to III, after at least three months of optimal medical therapy, in patients expected to survive substantially longer than one year with good functional status. In the 2021 ESC heart-failure guideline the class of recommendation depends on aetiology: Class I for ischaemic disease, Class IIa (level A) for non-ischaemic disease — the latter being the class that applies to DCM.^[27]

Cardiac resynchronisation therapy (CRT) is, in the 2021 ESC heart-failure guideline, Class I for QRS 150 ms or more with LBBB morphology, EF 35 percent or less, in sinus rhythm. It falls to Class IIa for QRS 130 to 149 ms with LBBB, or non-LBBB with QRS 150 ms or more, and CRT is not indicated when the QRS is under 130 ms. Prefer CRT-D (with defibrillator) in DCM unless contraindicated.^[27]

The high-arrhythmia genotypes — a named trap. In LMNA, FLNC, PLN, and RBM20 mutation carriers, malignant ventricular arrhythmia can precede contractile failure — so the standard EF-under-35 threshold will miss them.^[1] For LMNA the risk factors are defined: in a 269-carrier European cohort, non-sustained VT, LVEF under 45 percent at first contact, male sex and a non-missense variant each independently predicted malignant ventricular arrhythmia, and no event occurred in a carrier with fewer than two of the four — which is why an ICD is considered at a higher EF in this genotype.^[29]

Layer 4 — Anticoagulation

Anticoagulate for atrial fibrillation (by CHA2DS2-VASc), LV apical thrombus, or prior thromboembolism. In non-valvular AF the DOACs beat or match warfarin: apixaban 5 mg twice daily was superior to warfarin for stroke or systemic embolism with less bleeding and lower mortality (ARISTOTLE); rivaroxaban 20 mg daily was non-inferior (ROCKET AF); dabigatran 150 mg twice daily gave lower rates of stroke and systemic embolism than warfarin (RE-LY).^[11][12][13]

Layer 5 — Advanced therapies

Cardiac transplantation is the gold standard for end-stage DCM refractory to optimal therapy — indications include a peak exercise oxygen consumption of 14 mL per kg per min or less on formal testing (patients above this level have survival equal to post-transplant outcomes), recurrent hospitalisation, refractory ventricular arrhythmia, and cardiogenic shock needing inotropes or mechanical support.^[17] A durable LVAD is an option in advanced heart failure: in MOMENTUM 3, the fully magnetically levitated HeartMate 3 pump gave better six-month outcomes than the older axial-flow pump, mainly through fewer reoperations for pump malfunction and no pump thrombosis.^[22] Do not forget palliative care for the patient who is not a transplant candidate.

^{[1] [2] [27]}

The named subtypes that earn viva marks

Two subtypes come up again and again because each carries a mechanism, a treatment, and a recovery rate that examiners love. Peripartum cardiomyopathy and cancer-therapy-related cardiomyopathy are not footnotes — they are stems.^[1][8]

Peripartum cardiomyopathy — the 16-kDa prolactin fragment

PPCM is heart failure with EF under 45 percent in the last month of pregnancy or the first five months postpartum, with no other cause. The mechanism is a peripartum oxidative-stress cleavage of prolactin into a 16-kDa anti-angiogenic fragment that destroys the cardiac microvasculature — and that mechanism is the rationale for bromocriptine.^[8]

PPCM shares its genetics with DCM: in 172 women with PPCM, truncating variants in DCM genes were found in 15 percent — the same prevalence as in a DCM cohort (17 percent) and far above the 4.7 percent population rate — and two-thirds of them were in TTN, present in 10 percent of the women. A first-degree-relative history of DCM or sudden death should raise the index of suspicion in any breathless peripartum woman.^[8]

Management is standard GDMT modified for pregnancy and lactation, plus bromocriptine:^[15][16][23]

• Avoid ACEi, ARB, and MRA in pregnancy — teratogenic. Use hydralazine-nitrate for afterload reduction instead.
• Beta-blocker: metoprolol or bisoprolol.
• Start ACEi, ARB, and MRA postpartum if not breastfeeding.
• Bromocriptine — suppresses the 16-kDa prolactin fragment; the randomised comparison used 2.5 mg daily for 7 days (short course) or 5 mg daily for 2 weeks then 2.5 mg daily for 6 weeks (8-week course), with no significant difference between them (full recovery 52 versus 68 percent), so either is defensible. Guidelines say it may be considered, and because it stops lactation and carries a thrombotic risk it must be given with prophylactic or therapeutic anticoagulation — and breastfeeding must stop.^[15][30][27]
• Anticoagulation — given alongside bromocriptine-based therapy in most patients of the contemporary German cohort.^[9]

Recovery is the headline. In a contemporary German cohort of 66 women treated with standard heart-failure therapy, with a dopamine D2 agonist (mainly bromocriptine) and anticoagulation in 86 percent, mean EF rose from 26 ± 9 percent at diagnosis to 50 ± 11 percent at one year and 54 ± 7 percent at five years, with 72 percent achieving full cardiac recovery (Moulig, 2019) — far better than most DCM.^[9] Guidelines note recovery rates vary by region from 75 percent to under 50 percent.^[27] A subsequent pregnancy is the risk: heart-failure symptoms recurred in 44 percent of women with persistent LV dysfunction versus 21 percent of those whose EF had normalised, and mortality was 19 percent versus 0 percent.^[31]

Anthracycline versus trastuzumab — the Type 1 / Type 2 face-off

Cancer-therapy-related cardiomyopathy comes in two flavours, and the distinction is examined because the prognosis is opposite:^[1]

^{[1] [1] [33]}

The discriminator line: dose-dependent and irreversible = anthracycline (Type 1); not dose-dependent and reversible = trastuzumab (Type 2). Surveillance for both rests on echocardiographic monitoring of LV systolic function during treatment, supported by natriuretic peptides and troponin, with global longitudinal strain as the earliest flag before EF falls.^[27] Dexrazoxane is the one drug with trial evidence for prevention: in a Cochrane meta-analysis of seven adult trials it reduced clinical heart failure (RR 0.22, 95% CI 0.11 to 0.43) without harming tumour response or survival, so it is justified when the expected cardiac risk is high — but in children it may raise the risk of a second malignancy.^[37]

Screen the family — the single most under-applied life-saving intervention

If you do one thing after diagnosing DCM, screen the first-degree relatives. Familial disease is 30 to 50 percent of DCM, and a pathogenic variant is often found in a relative whose EF is still normal but whose ventricle is already dilating silently.^[1]

The standard is clinical evaluation, ECG, echocardiography and, where available, CMR in every first-degree relative, repeated every 5 years — or more often if the relative is under 50 or has non-diagnostic abnormalities. If a pathogenic variant is identified in the proband, offer targeted cascade genetic testing to first-degree relatives regardless of their phenotype: a carrier enters surveillance, a non-carrier is discharged. This is cheap, it is effective, and it is the intervention most consistently missed in routine practice.^[27]

Genetic testing with a targeted next-generation sequencing panel is recommended in any DCM with a family history, conduction disease (think LMNA), sudden death in the family, or onset under 50. Gene mutations are found in up to 40 percent of DCM overall, and in over 10 percent even of non-familial DCM — and each finding triggers cascade testing. The minimal panel is TTN, LMNA, MHC, TNNT, troponin-C, MYPC, RBM20, PLN, SCN5A, BAG3, cardiac actin, nexilin, tropomyosin-1 and vinculin.^[27]

Ward-round test — three stems

Stem 1 — the young man with a new failing ventricle and clean coronariesShowHide

A 29-year-old man presents with three months of progressive dyspnoea, two-pillow orthopnoea, and a family history of sudden death under 50. Echo shows a dilated thin-walled LV with EF 30 percent and functional MR; coronary angiography is normal. What is the aetiological work-up, and what is the first prescription? Model: This is non-ischaemic dilated cardiomyopathy by the 117-45 rule. The work-up is cardiac MRI (LGE pattern — mid-wall septal points to DCM, subepicardial inferolateral to myocarditis), a three-generation pedigree and targeted genetic panel (titin, LMNA, FLNC, PLN, RBM20), Holter for non-sustained VT and PVC burden, and a biochemical hunt for a reversible cause — alcohol history, thyroid function, iron studies, viral serology, ANA, and serum ACE. Start the four pillars together at low dose — ARNI (or ACEi after a 36-hour washout), carvedilol, MRA, SGLT2i — once euvolaemic, and titrate to target. Counsel on alcohol abstinence, and screen the first-degree relatives.^[1][2]

Stem 2 — the peripartum woman with EF 25 percentShowHide

A 31-year-old woman presents three weeks after an uneventful delivery with dyspnoea, orthopnoea, and bibasal crackles. Echo shows EF 25 percent with a dilated LV. She is breastfeeding and wants to continue. What changes about her heart-failure therapy? Model: This is peripartum cardiomyopathy — EF under 45 percent in the first five months postpartum with no other cause, driven by a 16-kDa prolactin fragment. Modify the GDMT for the puerperium: avoid ACEi, ARB, and MRA while she is pregnant or breastfeeding (guideline therapy respects pregnancy and lactation contraindications), use hydralazine-nitrate for afterload reduction and a beta-blocker, add a loop diuretic for congestion, give anticoagulation (mandatory if bromocriptine is used), and offer bromocriptine — either the 7-day 2.5 mg course or the 8-week course (5 mg daily for 2 weeks, then 2.5 mg daily for 6 weeks); the randomised comparison found no significant difference between them, and either means she must stop breastfeeding. Counsel that most recover substantially: in the German cohort mean EF rose from 26 to 54 percent, with full recovery in 72 percent at five years.^{[9][15][16][23][30]}

Stem 3 — non-ischaemic DCM, EF 32 percent after four months of optimal therapy, age 72ShowHide

A 72-year-old man with non-ischaemic DCM has been on target-dose ARNI, beta-blocker, MRA, and SGLT2i for four months. His EF has risen from 28 to 32 percent. He is NYHA II. The registrar books him for ICD implantation. What is the right conversation? Model: The DANISH trial (2016) showed an ICD did not reduce all-cause mortality in non-ischaemic systolic heart failure (21.6 versus 23.4 percent; HR 0.87), and the prespecified age analysis found the survival benefit confined to patients aged 70 or under. He technically meets the EF-under-35 threshold after three months of optimal therapy — a Class IIa indication in non-ischaemic disease — but this is a shared decision-making conversation, not an automatic implant. Lay out the small absolute mortality benefit, the risks (infection, inappropriate shock, lead failure), his competing non-arrhythmic risks, and the option of a wearable cardioverter-defibrillator or continued medical therapy. Check a CMR for mid-wall LGE and a genetic panel — high-arrhythmia genotypes (LMNA, FLNC, PLN, RBM20) shift the balance toward ICD even at this age. The patient decides with you, not the guideline alone.^{[7][28][5][27]}

The mantra

Dilated thin ventricle, find the cause, four pillars together, mid-wall scar predicts sudden death, screen the family.^[1][3]

References37ShowHide

1. [1]Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association Circulation, 2016.PMID 27832612
2. [2]Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases Eur Heart J, 2016.PMID 26792875
3. [3]McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J, 2023.PMID 37622666
4. [4]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines J Am Coll Cardiol, 2022.PMID 35379504
5. [5]Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy JAMA, 2013.PMID 23462786
6. [6]Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J, 2013.PMID 23824828
7. [7]Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure N Engl J Med, 2016.PMID 27571011
8. [8]Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies N Engl J Med, 2016.PMID 26735901
9. [9]Moulig V, Pfeffer TJ, Ricke-Hoch M, et al. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities Eur J Heart Fail, 2019.PMID 31724271
10. [10]Packer M, Bristow MR, Cohn JN, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group Circulation, 1996.PMID 8941105
11. [11]Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med, 2011.PMID 21870978
12. [12]Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med, 2011.PMID 21830957
13. [13]Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med, 2009.PMID 19717844
14. [14]Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med, 2009.PMID 19920054
15. [15]Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study Circulation, 2010.PMID 20308616
16. [16]Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy Basic Res Cardiol, 2013.PMID 23812247
17. [17]Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure Circulation, 1991.PMID 1999029
18. [18]Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med, 2004.PMID 15533851
19. [19]Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet, 2010.PMID 20801500
20. [20]The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med, 1997.PMID 9036306
21. [21]Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, 2019.PMID 30600580
22. [22]Mehra MR, Naka Y, Uriel N, et al. A fully magnetically levitated circulatory pump for advanced heart failure N Engl J Med, 2017.PMID 27959709
23. [23]Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy Eur J Heart Fail, 2019.PMID 31243866
24. [24]Fauchier L, Babuty D, Poret P, et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy Eur Heart J, 2000.PMID 10653678
25. [25]Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group N Engl J Med, 1996.PMID 8614419
26. [26]Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy N Engl J Med, 2012.PMID 22335739
27. [27]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J, 2021.PMID 34447992
28. [28]Elming MB, Nielsen JC, Haarbo J, et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure Circulation, 2017.PMID 28877914
29. [29]van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study J Am Coll Cardiol, 2012.PMID 22281253
30. [30]Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study Eur Heart J, 2017.PMID 28934837
31. [31]Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy N Engl J Med, 2001.PMID 11372007
32. [32]Nicolás JM, Fernández-Solà J, Estruch R, et al. The effect of controlled drinking in alcoholic cardiomyopathy Ann Intern Med, 2002.PMID 11827495
33. [33]Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer, 2003.PMID 12767102
34. [34]Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function Heart Rhythm, 2010.PMID 20348027
35. [35]Merlo M, Pivetta A, Pinamonti B, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years Eur J Heart Fail, 2014.PMID 24464640
36. [36]Merlo M, Pyxaras SA, Pinamonti B, et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment J Am Coll Cardiol, 2011.PMID 21435516
37. [37]de Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines Cochrane Database Syst Rev, 2022.PMID 36162822